GLP-1-based drugs close the treatment gap

The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2 diabetes. Until recently, bariatric surgery was often the only way to help severely obese patients reach their target weight. In the meantime, the marketing authorization of semaglutide and liraglutide has led to a breakthrough in the field of drug treatment options for obesity, and studies on tirzepatide show that this dual GIP/GLP-1 receptor agonist can achieve even better effects in terms of weight reduction.